Olezela (Omeprazole)

Omeprazole, the active ingredient in Olezela, is a Proton Pump Inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Olezela as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olezela as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton‑pump inhibitor that addresses disorders linked to excess gastric acid secretion.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid. - Helicobacter pylori eradication regimens (as adjunct): enhances eradication success when combined with antibiotics. - NSAID‑associated ulcer prophylaxis: lowers incidence of ulcer formation in at‑risk patients.

Adverse reactions to omeprazole are generally mild and dose‑dependent.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhea: loose stools occurring in a minority of patients. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Acute interstitial nephritis: sudden kidney inflammation. - Hypomagnesemia: low serum magnesium with prolonged therapy. - Stevens‑Johnson syndrome: rare severe skin reaction. - Fracture risk: possible increased risk of hip, wrist or spine fractures with long‑term use. - Liver enzyme elevation: uncommon rise in hepatic transaminases.

When prescribing omeprazole, clinicians should consider several safety aspects.

- Assess renal function: adjust use in severe renal impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term use: evaluate need for continued therapy after several months. - Pregnancy and lactation: weigh benefits against potential risks. - Elderly patients: use lowest effective dose and monitor for fractures. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, loss of antiviral efficacy. - Dasatinib: lowered plasma concentrations, reduced therapeutic effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Phenytoin: altered serum levels, adjust dosing as needed. - Methotrexate: increased exposure, especially with high‑dose regimens.